Identification, Molecular Epidemiology Angiosarcoma of the Liver France
NCT ID: NCT01786889
Last Updated: 2016-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
9 participants
INTERVENTIONAL
2013-06-30
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
NCT05390112
SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population
NCT05880173
Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease
NCT02060565
Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease
NCT01237574
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
NCT01492127
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Consultation:
* Study proposal
* Information and collection of the patient's and/or parent's written consents
* Blood collection (10ml) and urine collection of the patient and parents if applicable
* Delivery of a specific questionnaire and a stamped envelope (with the address of the coordinator's center). If it's about a child patient or an adolescent under 18 years, 3 questionnaires will be given (1 for each parent and 1 for the child).
At home: Filling the questionnaire by the patient and/or the parents, alone at home and return to the coordinator via the given envelope.
During the study: Collect of the initial biopsies used for the hepatic angiosarcoma's diagnostic.
End of the study: Telephone interview CRA/Patient and/or parents to complete the questionnaires (around one hour). From this data will be reconstitute the residential process of the patient and parents if it's about a child or an adolescent (collection of the successive addresses).
Finally, water collections, according to a defined sampling protocol, at the tap of the different homes and places visited by the patients will be organized by the InvS in relation to the ARS within the scope of water quality controls, in order to evaluate the exposition to vinyl chloride monomer (VCM) by hydric ways.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with angiosarcoma of the liver
Blood and urine collections, questionnaire and telephone interview
blood and urine
Blood collection and urine collection after consent of the patient
Questionnaire
The patient complete the questionnaire alone at home
Telephone interview
The patient will be contacted by the CRA for a telephone interview of around one hour
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood and urine
Blood collection and urine collection after consent of the patient
Questionnaire
The patient complete the questionnaire alone at home
Telephone interview
The patient will be contacted by the CRA for a telephone interview of around one hour
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient's written Consent
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de Veille Sanitaire
UNKNOWN
Centre Oscar Lambret
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
LE MOAL Joelle, Dr
Role: STUDY_DIRECTOR
Institut de Veille Sanitaire_Département Santé Environnement
PENEL Nicolas, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Oscar Lambret
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Bergonié
Bordeaux, , France
Centre Jean Perrin
Clermont-Ferrand, , France
Centre Georges François
Dijon, , France
Centre Oscar Lambret
Lille, , France
Centre Léon Bérard
Lyon, , France
Hôpital de la TIMONE
Marseille, , France
CRLCC Montpellier
Montpellier, , France
Hopital Tenon
Paris, , France
Institut de Cancérologie Lucien
Saint-Priest-en-Jarez, , France
CHU Strasbourg
Strasbourg, , France
Institut Claudius Regaud
Toulouse, , France
Chu / Hopital Trousseau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANGI HE-1110
Identifier Type: -
Identifier Source: org_study_id
2012-A00739-34 (IDRCB Number)
Identifier Type: OTHER
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.